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ABSTRACT 
 
The production of selective protein kinase inhibitors is often frustrated by the 
similarity of the enzyme active sites. For this reason, it is challenging to design 
inhibitors that discriminate between the three Aurora kinases, which are important 
targets in cancer drug discovery. We have used a triple point mutant of Aurora-A 
(AurAx3) that mimics the active site of Aurora-B to investigate the structural basis of 
MLN8054 selectivity. The bias toward Aurora-A inhibition by MLN8054 is fully 
recapitulated by AurAx3 in vitro.  X-ray crystal structures of the complex suggest that 
the basis for the discrimination is electrostatic repulsion due to the Thr217Glu 
substitution, which we have confirmed using a single point mutant. The activation 
loop of Aurora-A in the AurAx3/MLN8054 complex exhibits an unusual conformation 
in which Asp274 and Phe275 sidechains point into the interior of the protein. There is 
to our knowledge no documented precedent for this conformation, which have termed 
DFG-up. The sequence requirements of the DFG-up conformation suggest that it 
might be accessible to only a fraction of kinases. MLN8054 thus circumvents the 
problem of highly homologous active sites. Binding of MLN8054 to Aurora-A 
switches the character of a pocket within the active site from polar to hydrophobic 
pocket, similar to what is observed in the structure of Aurora-A bound to a compound 
that induces DFG-out. We propose that targeting this pocket may be a productive 
route in the design of selective kinase inhibitors and describe the structural basis for 
the rational design of these compounds.  
 
INTRODUCTION 
 
Following the success of Glivec in the treatment of chronic myelogenous leukaemia, 
the development of small molecule kinase inhibitors has become an established goal 
in drug discovery [1]. A major obstacle is that the ATP binding pocket, the ubiquitous 
druggable binding site for inhibitors, is highly conserved across more than 500 human 
kinases. The rapid growth in the number and chemical variety of kinase inhibitors has 
been aided by the contribution of structural biology especially the high resolution 
snapshots of kinase/inhibitor complexes captured by X-ray crystallography [1, 2]. 
These studies revealed the specific conformations recognized by the two main classes 
of kinase inhibitor. Type I inhibitors recognize the active, typically phosphorylated, 
form of the kinase, and Type II inhibitors recognize an inactive, typically 
dephosphorylated form of the enzyme. In Type I inhibitor co-crystal structures, the 
conformation of the activation loop, a motif containing the regulatory phosphorylation 
sites of kinases, adopts the same conformation as that observed in ADP/ATP-bound 
structures. This conformation is termed DFG-in after the highly conserved aspartic 
acid, phenylalanine, glycine motif at the N-terminus of the activation loop. In the 
DFG-in conformation, the aspartic acid sidechain points into the active site where it 
coordinates divalent cations and the phenylalanine sidechain points into the interior of 
the protein. By contrast, Type II compounds stabilize a DFG-out conformation of the 
activation loop, in which the phenylalanine sidechain points outwards and interacts 
with the compound and the aspartic acid sidechain is displaced away from the active 
site [3-5]. Structure-based drug design can be used to develop Type II, DFG-out 
binding compounds based on Type I, DFG-in binding precursors [6]. The field is still 
a long way from the direct rational design of selective and potent kinase inhibitors 
with a controlled selectivity profile. Currently, multiple iterative design cycles are 
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required to optimise compounds towards the desired biological profile. However, 
structural biology has provided insight and direction to the design of selective 
inhibitors that avoid off-target kinases. The selectivity profile of kinase inhibitors is 
very difficult to explain, even with the help of a high-resolution crystal structure. For 
example, nine years after the crystal structure of cAbl bound to a Glivec variant 
showed that this inhibitor recognizes the DFG-out conformation, there is still debate 
about the structural and thermodynamic basis for its selectivity [3, 7, 8]. It is clear, 
however, that the cAbl/Glivec variant structure was the inspiration for a new approach 
to kinase inhibitor design that has yielded many valuable compounds [6].  
 
Many mitotic kinases are promising cancer drug targets because they are 
overexpressed in tumours, and their inhibition generates an aberrant cell division that 
can selectively kill tumour cells [9]. A great deal of attention has been focused on the 
three Aurora kinases (A, B and C), and a number of structurally diverse inhibitors 
have been developed that target this family [10-12]. The Millennium Pharmaceuticals 
compound MLN8054 is an Aurora-family specific inhibitor that inhibits 7 out of 226 
kinases more than 50% at a concentration of 1 µM [13] or has a Kd < 100 nM for 6 
out of 317 kinases [14]. Unlike any of the other Aurora inhibitors, MLN8054 is based 
on a benzazepine scaffold and it has been of considerable interest to determine the 
binding mode of this compound and shed light on its specificity. MLN8054 is also the 
first inhibitor discovered to show increased selectivity towards Aurora-A both in a 
human colorectal tumour cell-line and in vitro [13, 14]. Aurora-A is amplified and/or 
overexpressed in many cancers and cancer cell lines including hepatocellular 
carcinoma [15], breast cancers [16] and neuroblastoma cell lines [16]. Polymorphisms 
in the Aurora-A gene confer increased breast and colon tumour susceptibility and 
somatic mutations in Aurora-A have been identified in colorectal adenocarcinoma, 
lung carcinoma and melanoma [17, 18]. Inhibition of Aurora-A may be a useful 
therapeutic strategy in these cancers, and clinical trials of several Aurora inhibitors, 
including a modified version of MLN8054 (MLN8237) are ongoing. 
 
The selectivity of MLN8054 can be considered as a function of two individual 
factors: bias towards Aurora-A, and selectivity towards the Aurora family. To 
investigate the first factor, we have studied the effects of MLN8054 on both Aurora-A 
and an Aurora-B active-site mimic (AurAx3). We find that MLN8054 exhibits a 6-fold 
stronger inhibition of Aurora-A than AurAx3 in vitro. The crystal structure of AurAx3 
bound to MLN8054 exhibits a highly unusual conformation of the activation loop. 
The characteristic features of the conformation are that both the aspartic acid and 
phenylalanine residues of the DFG motif point into the interior of the protein 
structure, and the activation loop wraps around the inhibitor and makes contact using 
a valine sidechain five residues after the start of the DFG motif. The structural details 
of this conformation, and a comparison of the key residues involved with those found 
in other human kinases show that it provides a rationale for understanding the 
selectivity of MLN8054 towards Aurora kinases. The binding of MLN8054 is 
accompanied by the creation of a hydrophobic pocket equivalent to that filled by the 
DFG Phe sidechain in a DFG-out structure. Our analysis suggests that a subset of 
kinases could be targeted through the design of inhibitors to fill this pocket, and that 
this would be an alterative route to producing highly specific compounds. 
 
MATERIALS AND METHODS 
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Chemical synthesis 
MLN8054 was synthesized as previously described [19]. 
 
Protein production and crystallization 
The Quikchange (Stratagene) method of site-specific mutagenesis was used to 
produce AurAx3 (Leu215Arg, Thr217Glu and Arg220Lys), AurATE (Thr217Glu) and 
AurAWL (Trp277Leu). AurA, AurAx3, AurATE and AurAWL proteins were expressed 
and purified as previously [20]. Crystals of AurAx3/MLN8054 were obtained using 
the hanging drop method of vapour diffusion. For the P31 form, the well buffer was 
0.8 M NaH2PO4/1.2 M K2HPO4 and 0.1 M acetate, pH 4.5. For the P6122 form, the 
well buffer was 0.1 M Mes sodium salt pH 6.5, 2.0 M ammonium sulfate, 5% (w/v) 
PEG400. Drops comprised a 1:1 ratio of AurAx3 at 7 mg/ml and 1 mM MLN8054 in 
DMSO. Crystals were briefly soaked in well buffer supplemented with 20% glycerol 
(P31) or 30% glycerol (P6122) before flash freezing in liquid nitrogen. 
 
In vitro kinase assays 
Kinase assays were carried out at room temperature using a Labchip EZ Reader II 
system (Caliper Life Sciences) and a fluorescein-labelled substrate peptide (5-FAM-
LRRASLG-CONH2) in a buffer of 50 mM Tris pH 7.5, 200 mM NaCl, 5 mM MgCl2, 
10% glycerol, 2% DMSO and 10 mM β-mercaptoethanol. 1 nM (AurA), 0.51 nM 
(AurAx3), 0.15 nM (AurATE) or 0.4 nm (AurAWL) enzyme in duplicate were pre-
incubated in 25 µl reaction volume with 1.5 µM substrate peptide and stated 
concentration of MLN8054 for 10 mins before starting the reaction with stated 
concentrations of ATP. Measurements of substrate phosphorylation were taken every 
5 mins for 1 hr (AurA, AurATE and AurAWL) and 30 mins (AurAx3). In the 
experiments to measure the effect of TPX2 on the potency of MLN8054, 3.4 µM 
TPX2 (residues 1-43) was pre-incubated with AurA for 10 mins before the addition of 
MLN8054 and substrate. This concentration is 340 times the EC50 of TPX2, which 
was determined to be 10 nM under conditions of saturating ATP. All measurements 
conformed to the linear initial rate assumption and best-fit rates were used to 
construct rate v [ATP] curves. Data were fitted to a global model for competitive 
inhibition using Prism5 (www.graphpad.com). 
 
Crystallographic data processing and refinement 
Diffraction data was reduced using Mosflm, scaled with Scala and the molecular 
replacement solutions were obtained with Phaser using the structure of ADP-bound 
Aurora-A as a model [21]. Four AurAx3 molecules were located in the P31 
asymmetric unit, exhibiting clear difference density corresponding to two different 
conformations of the activation loop. Coordinates and refinement parameter (.cif) 
files for the MLN8054 ligand were made using Phenix [22]. Iterative cycles of model 
building and refinement were carried out using Coot and Phenix [21, 22]. All 
structure figures were produced using PyMOL (http://www.pymol.org). 
 
Sequence analysis of the human kinome 
The human ePK alignment containing 491 kinase domains, available at 
http://www.kinome.com, was used as the basis for calculating the frequency of amino 
acids at specific positions within the sequence as shown in Table 3 [23]. The sequence 
alignment was interrogated using a custom Perl script, available upon request.  
 
Accession Codes 
Biochemical Journal Immediate Publication. Published on 12 Jan 2010 as manuscript BJ20091530
TH
IS
 IS
 N
O
T 
TH
E 
VE
RS
IO
N 
O
F 
RE
CO
RD
 - 
se
e 
do
i:1
0.
10
42
/B
J2
00
91
53
0
A
ce
pte
d M
an
us
cri
pt
Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
© 2010 The Authors Journal compilation © 2010 Portland Press Limited
 5
Coordinates and structure factors of AurAx3/MLN8054 structures have been deposited 
in the Protein Data Bank (PDB) with accession code 2WTV (P31) and 2WTW 
(P6122). 
 
RESULTS 
 
Characterisation of an active-site model of Aurora-B 
 
The catalytic domains of human Aurora-A and Aurora-B are 76% identical at the 
primary sequence level, and differ by just three amino acids in their ATP-binding 
pockets - residues Leu215, Thr217 and Arg220 in Aurora-A are replaced by Arg159, 
Glu161, and Lys164 respectively in Aurora-B. To date, comparative studies have 
been frustrated because human Aurora-B has poor physico-chemical properties 
relative to Aurora-A and has not been crystallized. We constructed a triple point 
mutant version of the catalytic domain of Aurora-A (residues 122-403, Leu215Arg, 
Thr217Glu, Arg220Lys), which we call AurAx3, as an Aurora-B active site mimic for 
crystallographic studies and to assess the contribution of the three residues to 
selectivity of MLN8054. The resulting enzyme is catalytically active, with kinetic 
parameters very similar to those for wild-type Aurora-A catalytic domain, which we 
call AurA (Figure 1a, Table 1). MLN8054 acts as an ATP-competitive inhibitor for 
both enzymes (Lineweaver-Burke plots intersecting on y-axis, data not shown) and 
the resultant Kis show a 6-fold discrimination for AurA over AurAx3, greater than that 
which can be explained by the relative Kms of the active site for ATP alone. This level 
of discrimination compares well with the 7-fold difference in dissociation constants 
reported in the absence of ATP using bead-based competition binding assays [14] 
although we report a consistently tighter binding (0.3 nM compared with 6.5 nM and 
1.8 nM compared with 43 nM for Aurora-A and Aurora-B respectively). We have 
used equation (1) and our measured Ki to calculate the IC50 we would expect to 
measure for AurA under the experimental conditions reported for radioactive 
FlashPlate assays [13]. The calculated value of 3 nM compares very well with the 
published IC50 of 4 nM although we should point out that the extremely tight binding 
of MLN8054 means that the IC50 contains a large contribution from the assay enzyme 
concentration. A similar calculation for Aurora-B using the Ki for AurAx3 and a 
commercially reported Km for Aurora-B (5 µM, 
http://www.caliperls.com/products/aurb-h.htm) is within a factor of two (calculated 
93 nM, reported 172 nM).  
 
IC50 = Ki 1+ SKm
⎛ 
⎝ ⎜ 
⎞ 
⎠ ⎟ +
[enzyme]
2
       (1) 
 
We can thus conclude that the three point mutations differentiating AurAx3 and AurA 
provide a good model for assessing the contribution of active site residues to the 
binding of MLN8054. Interestingly, the difference between our measured Km for ATP 
for AurAx3 (46 µM) and the reported value for AurB (5 µM) means that we would 
expect additional residues outside the active site pocket to influence the binding of 
ATP. 
 
Binding mode of MLN8054 in the active site of Aurora kinase 
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The chemical structure of MLN8054 is shown in Figure 1b. AurAx3 was co-
crystallised with MLN8054 and the structure determined to a resolution of 2.4 Å 
(Table 2). There are four AurAx3 molecules in the asymmetric unit that adopt two 
slightly different protein conformations of which chains A and B are representative 
(Figure 2a). The two conformations are the result of two different crystal packing 
contacts between the activation loop and a neighbouring molecule (stars in Figure 2a). 
The structure of Aurora-A catalytic domain mutated on the two sites of auto-
phosphorylation (Thr287Ala, Thr288Ala), which we shall refer to as AurAAA, bound 
to the 8054-like compound (shown in Figure 1b), has recently been determined (PDB 
code 3H10, [24]). This complex crystallized in a different crystal form (P212121) to 
the AurAx3/MLN8054 (P31). In chains A and B of this structure the activation loop of 
AurAAA has a very similar conformation to that found in chain B of the 
AurAx3/MLN8054 structure and is involved in different crystal packing contacts 
(Figure 2a). The activation loop is disordered between residues 284-291 in the third 
chain (D) of the AurAAA/8054-like structure, which presumably cannot form a 
stabilizing crystal packing contact. 
 
Additional electron density within the active site of AurAx3 was very clear, and the 
MLN8054 ligand was fitted unambiguously (Figure 2b). The two different 
conformations of AurAx3 are in fact very similar in the vicinity of MLN8054, with the 
exception of residue Glu217, one of the residues mutated to mimic Aurora-B. In 
chain A Glu217 is closest to the benzoic acid moiety of MLN8054 (3.8 Å 
shortest interatomic distance), whereas in chain B Glu217 is closest to the 
difluorophenyl group (4.7 Å shortest interatomic distance). The active site of 
AurAAA bound to the 8054-like compound is very similar in all three chains and is 
very similar to that of either of the two chains of AurAx3 bound to MLN8054 (Figure 
2b). In the structure of AurAAA/8054-like, the methyl group of Thr217 is closest 
to the difluorophenyl group (3.6-3.8Å). The substitution of Glu for Thr at 
position 217 has no effect on the binding mode. However, the individual 
Thr217Glu point mutant of Aurora-A (AurATE) is almost 20-fold less potently 
inhibited by MLN8054 than the wild-type AurA (Figure 1, Table 1). The 
difference in potency of MLN8054 inhibition between AurA and AurAx3 is 
therefore primarily due to the Thr217Glu mutation. The difference is modest 
because there is no steric clash and hence no change in binding mode, and 
the flexibility of the Glu217 sidechain reduces the effectiveness of 
the repulsion between the ionised glutamate and the hydrophobic 
difluorophenyl or benzoic acid groups of MLN8054.  With the exception of 
Glu217, the interactions between MLN8054 and AurAx3 chains A and B are identical, 
as are the contacts between AurAAA and the 8054-like compound. MLN8054 forms 
two H-bonds with the hinge region of AurAx3 at Ala213, and a water-mediated H-
bond to Asp274 (Figure 2c). The aromatic benzoic acid group sits above the Cα of 
Gly216 in a position similar to that occupied by aromatic rings in other Aurora 
inhibitor structures  (e.g. PDB codes 2BFY [25], 2W1I [26]). The chlorine atom and 
the aromatic ring to which it is attached pack against the Gly-rich loop. The 
difluorophenyl group packs against Leu263, Ala273 and Val279, which also packs 
against the chlorine atom. With the exception of the acidic group, the entire molecule 
of MLN8054 is buried inside the active site pocket of AurAx3. Remarkably, this is 
achieved in part by the remodeling of the activation loop conformation to wrap 
around part of the inhibitor. 
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 7
The conformation of the activation loop induced by binding of MLN8054 
 
The conformations of the activation loop adopted by AurAx3 bound to MLN8054 and 
AurAAA bound to the 8054-like compound are highly unusual. The activation loop is 
flipped around compared to the DFG-in conformation observed in the ADP-bound 
AurA structure [20] and superficially resembles a DFG-out conformation, as observed 
in AurA/quinazoline-13 or cAbl bound to a Glivec variant (Figure 3a, PDB codes 
2C6E and 1FPU respectively [3, 27]). Upon closer inspection, the conformation of the 
activation loop of AurAx3/MLN8054 is clearly different. In DFG-in and DFG-out 
conformations of kinases, the aspartic acid and phenylalanine sidechains sit on 
opposite sides of the backbone. In these conformations, when the phenylalanine 
sidechain points into the interior of the protein, the aspartic acid sidechain points out 
into the active site and vice versa (Figure 3b). By contrast, in the AurAx3/MLN8045 
and AurAAA/8054-like structures, both Asp274 and Phe275 project up into the interior 
of the kinase (Figure 3b,c). For this reason, and for the sake of brevity, we shall refer 
to this conformation as DFG-up.  
 
The DFG-up conformation is characterized by a substantial reorganization of the 
activation loop between residues 274-293 and the HRD-motif at residues His254 and 
Arg255. Compared with the DFG-in conformation, the sidechain of Asp274 is rotated 
by approximately 180° so that it points into the interior of the protein, parallel to helix 
αC (Figure 3b). The sidechain of Phe275 points inwards and occupies a pocket above 
the Glu181 sidechain, whereas in the DFG-in conformation Phe275 occupies a pocket 
below Glu181. The Glu181 sidechain makes a H-bond with the indole ring of Trp277, 
which is twisted around from its outward position in the DFG-in conformation. 
Glu181 is a crucial residue for catalysis because it forms a salt bridge with Lys162 
that positions the phosphates of ATP for transfer to substrate. In the DFG-up 
conformation, Lys162 forms a H-bond with Ser278 of the activation loop. Thus, 
although the salt bridge is broken in the DFG-up conformation, both residues find 
alternative partners with which to form H-bonds. The conformational change in the 
activation loop moves the Cα of Val279 approximately 19 Å compared to its position 
in the DFG-in structure. Val279 can thus make two points of contact with 
MLN8054/8054-like. Beyond Val279, the conformations of chains A and B deviate 
until the end of the activation loop (Leu293), and the differences are likely due to the 
different crystal packing contacts (Figure 2a). The sidechains of the HRD motif are 
switched in the DFG-up structure. His254 points outwards, whereas in the DFG-in 
conformation it usually points inwards and stacks against Phe275. Arg255 points 
inwards and interacts with Asp274 (DFG motif) and Asn185 (helix αC), whereas it  
normally faces outwards, and recognises the phosphorylated Thr288 in an active 
AurA structure (PDB code 1OL5 [20]).  
 
The DFG-up conformation is distinct from the DFG-out conformation that is observed 
in the structures of quinazoline-13 bound to Aurora-A or a Glivec variant bound to 
cAbl. Apart from the differences in the DFG motif, in the DFG-out conformation 
Trp277 interacts with the quinazoline-13 inhibitor and the arrangement of the HRD-
motif is similar to that found in the DFG-in conformation. Additionally, structures of 
Aurora-A and cAbl in the DFG-out conformation are of dephosphorylated kinases,  
whereas the DFG-up is observed with either phosphorylated or unphosphorylated 
Aurora-A. We speculate that phosphorylated Aurora-A can adopt DFG-up (and 
probably DFG-out) conformations without much energetic penalty because the 
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phosphorylated activation loop of Aurora-A is not stably locked in the active 
conformation except in the presence of TPX2 [20]. One prediction from the 
AurAx3/MLN8054 structure is that the binding of TPX2 should decrease the potency 
of MLN8054 either through competition or because more energy is required to move 
the activation loop from its stable, active conformation into DFG-up. We determined 
the Ki for MLN8054 for AurA in the presence of a saturating concentration of TPX2 
to be 3.3 ± 0.2 nM, a substantial increase on the Ki in the absence of TPX2 
comparable to that obtained with AurAx3 or AurATE (Figure S1, Table 1, Table S1).  
 
Insights into the selectivity of MLN8054 for Aurora kinases 
 
Close inspection of the structure shows that many of the interactions between residues 
proximal to the active site are rearranged with respect to previous Aurora-A 
structures. This observation led us to consider whether other kinases might be able to 
adopt a similar conformation and if this might have any bearing on the selectivity of 
MLN8054. A search of the published alignment of human kinases and a search using 
the ProSite server reveals that only Aurora kinases possess a tryptophan at the 
equivalent position to 277, three residues after the start of the DFG motif (D+3, Table 
3) [23]. Most of the more frequent residues at this position are hydrophobic and could 
not form a H-bond with Glu181. The exception to this is serine, found in 7.5% of 
kinases, although the position of the sidechain would have to be shifted by 2 Å to 
make the H-bond. In addition, Trp277 makes hydrophobic contacts with Phe144 and 
Val174 that could not be made by a serine sidechain. We mutated AurA at Trp277 to 
leucine, the most common residue at this position in human protein kinases. The Ki 
for MLN8054 for AurAWL was determined to be 4.4 ± 0.4 nM, comparable to that 
determined for AurAx3 or AurATE (Figure S1, Table S1). This supports our suggestion 
that the unusual tryptophan residue at position 277 contributes to MLN8054 
selectivity towards Aurora kinases. Val279 at D+5 is also unusual at its position in the 
kinase domain and is found in less than 5% of kinases (Table 3). In most kinases that 
are regulated by phosphorylation of the activation loop the equivalent residue at this 
sequence position is most frequently a lysine or arginine, which interacts with the 
activating phosphate group (i.e. on a residue equivalent to Thr288) and helps order the 
activation loop. Full ordering of the activation loop of Aurora-A proceeds by a 
different mechanism than most kinases because binding of an activator such as TPX2 
is required in addition to phosphorylation on Thr288 [20]. The interior surface of 
Aurora kinases that is contacted by the DFG motif in the DFG-up conformation is 
highly unusual. In most kinases, this region is hydrophobic, and in particular there is a 
conserved hydrophobic residue on the αC helix that forms part of the hydrophobic 
spine of kinases and interacts with the Phe sidechain of the DFG motif in the DFG-in 
conformation [28]. Across all human kinases, this residue is a leucine in 53% of 
cases, and a methionine in 25%. In the Aurora family, this hydrophobic residue is 
replaced by Gln185, which makes a H-bond with the backbone at Leu194. The 
presence of Gln185 is presumably important for the DFG-up conformation because it 
lies at the centre of a network of polar interactions that involves the sidechains of 
Asp274, Arg255 and the backbone at Leu194. Only COT, a mitogen-activated protein 
kinase kinase kinase, has both equivalent identical residues to Gln185 and Val279, 
and no other kinase has even a related combination (Ile or Leu for Val, His or Asn for 
Gln). The Aurora family thus has a unique set of features that create the capacity to 
adopt the MLN8054-bound activation loop conformation: the presence of the polar 
back pocket, the lack of a basic residue at D+5 and the tryptophan at D+3. This 
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suggests that the conformation of AurAx3 bound to MLN8054 might not be easily 
accessible to other kinases, and might thus contribute to the selectivity of MLN8054. 
 
A model to explain the structural and chemical basis for the conformational 
changes in DFG-out and DFG-up conformations of Aurora-A 
 
We obtained a second crystal structure of the complex at 3.3Å resolution 
(AurAx3/MLN8054*) in a P6122 crystal form that is very commonly obtained with 
AurA (Table 2). In this structure, the activation loop adopts a DFG-in conformation 
(Figure 4a, b). This may simply represent a crystallization artefact, because the crystal 
packing is incompatible with the DFG-up conformation of the activation loop, which 
appears to be trapped in the DFG-in conformation by crystal packing contacts. When 
compared to the ADP-bound AurA structure, there is a steric clash between the Gly-
rich loop in the ADP-bound conformation and MLN8054 (star, Figure 4b). In the 
AurAx3/MLN8054* structure the Gly-rich loop is displaced upwards due to contacts 
between MLN8054 and the Gly-rich loop at the sidechain at Val147 and the 
mainchain at residues 140-141 (Figure 4b). The AurAx3/MLN8054* structure shows 
that the MLN8054 can be accommodated in the active site without movement of the 
activation loop, but requires displacement of the Gly-rich loop. Superposition of the 
higher resolution AurAx3/MLN8054 or AurAAA/8054-like structures show the same 
steric clash between the Gly-rich loop of the ADP-bound structure with MLN8054 
and a second steric clash between the Gly-rich loop of the ADP-bound structure (at 
residues 142-143) with the activation loop of the MLN8054-bound structure at 
Val279 (Figure 4c). The higher resolution structures show a displacement of the Gly-
rich loop similar to that observed at low resolution in the AurAx3/MLN8054* 
structure. It appears that the upwards movement of the Gly-rich loop is a necessary 
adjustment to accommodate the activation loop in the DFG-up conformation, and 
could be an initial first step upon binding of MLN8054 to Aurora-A.  
 
The fact that the DFG-up conformation has not been reported before suggested to us 
that there is something unusual about the binding of MLN8054 that induces this 
conformation. The superposition of AurA/ADP with AurAx3/MLN8054 shows that 
the difluorophenyl group of MLN8054 occupies the equivalent space to that occupied 
by the α-PO4 group of ADP, which we shall refer to as the α-PO4 space (Figure 4d). 
The two groups have vastly different chemical properties, and the properties of this 
space are altered between DFG-in and DFG-up conformations. In the DFG-in 
conformation, Asp274 sits to one side of the α-PO4 space and together with Asn261 
coordinates two divalent cations (e.g. Mg2+) that stabilise the ADP/ATP phosphates. 
In the DFG-up conformation, Asp274 is flipped and the Mg2+ binding sites are 
eliminated. The movement of Val279 completes the conversion of the α-PO4 space to 
a hydrophobic pocket, which is occupied by the difluorophenyl group of MLN8054 
(Figure 3b, 4d). The DFG-up conformation of Aurora-A could therefore be driven by 
the occupation of the α-PO4 space by the difluorophenyl group of MLN8054. 
Interestingly, a similar change to the chemical properties of the α-PO4 space occurs in 
the DFG-out conformation. In fact, the DFG-up and DFG-out conformations are 
clearly related and they possess two equivalent hydrophobic pockets that can be filled 
by a phenyl group (yellow, green dashed circles Figure 4e). The groups which occupy 
these two pockets in the DFG-up or DFG-out conformations display a degree of 
symmetry. In the DFG-out conformation, the α-PO4 space is occupied by the Phe275 
sidechain and the second pocket is filled by the quinazoline-13 compound (Figure 3b, 
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4e). In the DFG-up conformation, the α-PO4 space is occupied by the difluorophenyl 
group of MLN8054 and the second pocket is filled by the sidechain of Phe275. 
Further exploration of the chemical, structural and biophysical relationship between 
these two conformations may be beneficial in the production of more selective Aurora 
compounds. 
 
DISCUSSION 
 
The observation of the same, unusual activation loop conformation induced by two 
similar compounds bound to variants of the protein which are unphosphorylated 
(AurAAA) or phosphorylated with mutations in the active site (AurAx3), and which 
were crystallized in two different crystals forms, is strong evidence that this 
conformation is neither an artefact of any of the protein modifications nor an artefact 
of crystal packing, but is driven by binding of the MLN8054/8054-like compounds. 
This raises the concern that selectivity testing for MLN8054 may be difficult to 
interpret because the inhibitor might be expected to bind more tightly to off-target 
kinases in the inactive state rather than the active proteins which are used in assay 
screens. Our analysis of the sequence requirements for the DFG-up conformation 
raises the question of how MLN8054 is able to inhibit several other kinases, albeit 
with lower potency than the Aurora family, such as Abl (76% inhibition at 1 µM) and 
Yes (80% inhibition at 1 µM) [13]. It is possible that these kinases are able to adopt 
the DFG-up conformation, and that the lower potency is partly because this 
conformation is a less favoured, higher energy state. Alternatively, MLN8054 could 
bind to these kinases in a different conformation, such as the DFG-in conformation 
observed in the low-resolution AurAx3/MLN8054* structure. The determination of the 
selectivity profile of this class of inhibitor is therefore perhaps most accurately 
achieved by using a direct binding screen against inactive and active forms of the 
kinases[14]. Rational design and prediction of selectivity profiles remains an 
extremely difficult challenge given the existence of multiple inactive conformations 
accessible to protein kinases and the possibility that some compounds might be able 
to target more than one conformation.  
 
It has been suggested that Thr217 might be the basis for the higher potency of 
MLN8054 for Aurora-A over Aurora-B[24]. We have now confirmed that Thr217 is 
the main determinant of its bias towards Aurora-A in vitro and shown the relative 
disposition of a glutamic acid sidechain at this position in the crystal stucture.  
MLN8054 does not fully utilize the potential of the Thr217Glu substitution to 
generate selectivity, because the compound does not sit very close to residue 217 and 
can still be accommodated when the residue is substituted for glutamic acid. The 
selectivity of MLN8054 for Aurora-A over Aurora-B in vitro is not high, only 
approximately 6-fold using strictly comparable Ki or Kd measurements. In contrast, 
MLN8054 is over 100-fold selective for Aurora-A over Aurora-B in cell-based assays 
and the compound can be used to obtain a cellular phenotype consistent with clear 
discrimination [13, 29]. The Aurora-A activator TPX2 reduces the potency of 
MLN8054 versus Aurora-A, although only a specific pool of Aurora-A localized to 
mitotic spindle microtubules is thought to be bound to TPX2. The cellular potency of 
Aurora-A might be due to targeting the non-TPX2-bound pool of Aurora-A. The 
mechanism by which Aurora-B is only poorly inhibited by MLN8054 in cells is 
presently unclear. It is possible that Aurora-B is prevented from adopting the DFG-up 
conformation through binding to a protein partner, but it is not obvious how this could 
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be mediated from current structures of the Aurora-B/INCENP complex. The 
elucidation of this mechanism may be important for understanding the cellular 
regulation of these kinases. 
 
The structure of AurAx3 bound to MLN8054 suggests that the specificity of this 
compound for the Aurora family is at least partly a function of the protein 
conformation it induces. This does not imply that we believe it to be impossible to 
produce inhibitors that target other kinases in a DFG-up conformation. On the 
contrary, it might be possible to exploit the principle behind the DFG-up 
conformation to generate compounds that induce the DFG-up conformation of other 
kinases, just as it has been possible to generate potent inhibitors that bind the DFG-
out conformation of a number of kinases. This is because the conformation induced 
by these compounds would be DFG-up, but would differ in the precise details of the 
conformation adopted by the activation loop, especially the residues just after the 
DFG motif. One feature that is potentially vital for adopting a DFG-up conformation 
is the polar residue on the C-helix (Gln185), and an equivalent polar residue is present 
in just under 10% of human kinases. We predict that these would be the most likely 
targets for DFG-up inhibitors. The other key features of the DFG-up conformation are 
the interactions within the kinase domain and between the activation loop at D+5 
(Val279) and the inhibitor. To design a DFG-up targeting inhibitor, we predict that 
one should modify a Type I inhibitor with the addition of a hydrophobic group to fit 
the α-PO4 pocket that is complementary to the residue at D+5. One might expect that 
this would only work with kinases that possess residues at D+3 and D+4 capable of 
making compensating interactions with the disrupted Lys-Glu salt bridge residues. 
Future studies will elaborate which other kinases can be induced to form the DFG-up 
conformation. Furthermore, the discovery of the DFG-up conformation, and our 
recent discovery of multiple, stable, ligand-induced conformations of Nek2 kinase 
[30] suggest to us that the conformational space of the activation loop should be 
further explored, and exploited to produce selective inhibitors. 
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FIGURE LEGENDS 
 
Figure 1. Comparison of AurA, AurAx3 and AurATE kinetic parameters and 
MLN8054 inhibition 
a) Global fits of apparent ATP Km in presence of varying concentrations of 
MLN8054: 0 nM (black), 0.02 nM (dark grey, AurA only), 0.06 (light  grey, AurAx3 
and AurATE only, filled circles), 0.2 nM (black), 0.6 nM (dark grey), 2 nM (light grey, 
open circles), 5 nM (black), 16 nM (dark grey), 50 nM (light grey, AurAx3 and 
AurATE only, diamonds). Error bars and quoted errors are fitting errors of duplicate 
measurements. The average of three repeat measurements in duplicate for AurAx3 did 
not alter the Ki or Km, and standard errors of these values were the same magnitude as 
fitting errors quoted. 
b) Chemical structures of MLN8054, the 8054-like compound [24] and quinazoline-
13 [27]. 
 
Figure 2. Binding mode of MLN8054 
a) Two different conformations of AurAx3 are shown as yellow cartoons, with 
MLN8054 shown as spheres using the colour scheme carbon grey, nitrogen blue, 
oxygen red, chlorine green and fluorine cyan. The structure of AurAAA is shown as an 
orange cartoon, with the 8054-like compound shown in the same colour scheme as 
MLN8054. Crystal contacts that direct the different paths of activation loops are 
marked with stars, and the neighbouring protein molecule is depicted as grey cartoon. 
b) Magnified view of the active site. The mainchain of AurAx3/AurAAA is shown as a 
Cα trace. MLN8054/8054-like and residues lining the active site of AurAx3/AurAAA 
are shown in stick representation. The final 2mFo-dFc electron density map around 
MLN8054 is shown as a wiremesh contoured at 1.0σ. 
c) Magnified view of the active site shown in a view rotated through approximately 
90º about the horizontal axis relative to (b). Putative H-bonds are shown as dashed 
lines, and an ordered water molecule that mediates contact between the ligand and the 
protein is shown as a red sphere. The sidechain of Tyr212 is omitted so that the H-
bonds between Ala213 and the ligand are not obscured.  
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Figure 3. Comparison of the activation loop conformations in the 
AurAx3/MLN8054 structure with those of DFG-in and DFG-out structures 
a) Cartoon representation of kinase structures with the activation loop highlighted in 
magenta and the ligand shown as grey spheres. From top to bottom the structures 
shown are AurAx3/MLN8054 (chain A), AurA/ADP (PDB code 1OL7 [20]), 
AurA/quinazoline-13 (PDB code 2C6E [27]), and cABL/Glivec variant (PDB code 
1FPU [3]).  
b) Magnified stereo views of the active site of AurAx3/MLN8054 (chain A), 
AurA/ADP and AurA/quinazoline-13 in the same orientation as in (a). The N-
terminal residues of the activation loop (ADFGWSV), the HRD-motif residues and 
the two residues that form an important salt bridge in the active enzyme (Lys162-
Glu181) are shown in stick representation.  
c) Magnified stereo view of AurAx3/MLN8054 (chain A) oriented to give a clear view 
of the interactions between the activation loop residues and the interior of the protein. 
The backbone of AurAx3 is shown as a Cα trace, key residues and MLN8054 are 
shown in stick representation. 
 
 
Figure 4. Activation loop conformational differences between Aurora-A 
structures are perhaps driven by the chemical group that occupies the α-PO4 
space 
a) Superposition of AurA/ADP (protein dark teal cartoon, ADP dark teal sticks, PDB 
code 1OL7 [20]) with the 3.3 Å resolution AurAx3/MLN8054* structure (protein pink 
cartoon, MLN8054 pink sticks). 
b) Magnified view of the superposition, with mainchain shown as ribbon and key 
residues shown as sticks and the ADP molecule omitted for clarity. The final 2mFo-
dFc electron density map around MLN8054 is shown as a wiremesh contoured at 
1.0σ. The steric clash between the Gly-rich loop (shown as a thicker ribbon) in the 
ADP-bound structure and MLN8054 is highlighted with a black star. 
c) Superposition of chain A of AurAx3/MLN8054 structure (chain A, protein yellow 
ribbon, MLN8054 grey sticks) with structure of phosphorylated, ADP-bound AurA 
(protein dark teal ribbon, ADP dark teal sticks, PDB code 1OL7 [20]). Key regions of 
conformational difference are marked. 
d) Magnified view of superposition to show detail of active site. The upper panel is 
depicted in the same orientation as (c), the view in the lower panel is rotated through 
90º about the vertical axis. Steric clashes between MLN8054 or the activation loop of 
MLN8054-bound AurAx3 and the Gly-rich loop of ADP-bound AurA are highlighted 
with single and double stars respectively. Magnesium ions in the ADP-bound 
structure are depicted as spheres. In the lower panel, the deviation between the two 
structures starting from Asp274 in the activation loop is clearly evident.  
e) Comparison of the phenyl-binding pockets of the three different DFG motif 
conformations. The left-hand images show simplified structural models of the three 
conformations viewed from the back of the active site looking out to solvent (i.e. 180º 
rotation relative to the top panel of Figure 4d). The mainchain of the DFG motif is 
shown as a magenta cartoon, the Asp274 sidechain is shown as magenta space-filling, 
the sidechain of Phe275 as dark grey space-filling and the ligand as space-filling with 
the following colour scheme: carbon light grey, nitrogen blue, oxygen red, 
phosphorous orange, fluorine cyan. The right-hand images show a schematic diagram 
of the comparison. The α-PO4 space is shown as a dashed yellow circle and the 
second phenyl-binding space is shown as a dashed green circle. The pocket occupied 
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by Phe275 in the DFG-in conformation does not coincide with the other two pockets 
and is shown as a dashed black circle. The aspartic acid and phenylalanine residues of 
the DFG motif are depicted with magenta and black lines respectively. Relevant 
features of the three ligands are shown as follows: the two phosphate groups of ADP 
as red stars; the terminal phenyl group of quinazoline-13 as a grey hexagon; the 
difluorophenyl group of MLN8054 as a modified grey hexagon. 
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Table 1. Summary of parameters determined for kinase activity and inhibition 
by MLN8054
 AurA AurAx3 AurATE
Km, ATP (?M)  20 ± 2 46 ± 3 72 ± 5 
kcat (min
-1)a   4.8 ± 0.7 8.1 ± 1.2 52.4 ± 7.5 
Ki (nM) 0.27 ± 0.03 1.8 ± 0.2 5.2 ± 0.3 
a) Errors on kcat are propagated from the fitting error on Vmax, assuming a 10% error in 
the determination of the final concentrations of enzyme and peptide. The Km for ATP 
for AurA is in excellent agreement with the previously published value 30.
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Table 2.  Summary of crystallographic analysis 
Crystals  AurAx3/MLN8054 AurAx3/MLN8054*   
Spacegroup  P31 P6122
Lattice constants  a (Å)  118.71 84.04  
 b (Å)  118.71 84.04  
 c (Å)  135.89? 171.06 ?
Data collection    
Resolution range (Å)  59.3 - 2.4 72.9 - 3.3  
(Highest resolution shell)  (2.53 - 2.40) (3.30-3.48)  
Unique reflections  83351 (11952) 5790 (815)  
Completeness(%)  99.5 (97.6) 99.6 (99.5)  
Multiplicity  3.4 (2.7) 14.8 (14.8)  
Rmerge (%)  8.3 (34.6) 11.6 (46.7)  
I/?(I)  12.3 (3.2) 20.6 (7.7)  
Refinement 
Resolution range  19.8 - 2.4 67 - 3.3  
Number of reflections  79178 5738  
Rfactor (%)  16.4 23.4  
Rfreea (%)  21.1 28.8   
R.m.s. deviations 
    Bond lengths (Å)  0.005 0.004  
    Bond Angles (?)  1.05 0.820  
Ramachandran outliers (%) 0.0 0.4   
Ramachandran favoured (%) 98.4 92.9  
a Free Rfactor was computed using 5% of the data assigned randomly.
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Table 3.  Frequency of amino acids in the N-terminus of human kinase domain 
activation loops 
Aurora-A kinase residue numbering
D  D+1  D+2  D+3  D+4  D+5 
274  275  276  277  278  279 
Frequency of occurrence in human ePK kinase domain sequences1
           
Asp (458) Phe (403) Gly (446) Leu (245) Asp (247) Arg (157) 
  Leu (50)   Phe (58) Ser (144) Lys (109) 
  Tyr (18)   Ser (37) Cys (42) Thr (33) 
      Met (34) Thr (18) Ala (30) 
      Val (31) Gly (15) Val (23)
      Ile (23)   Ser (22) 
      .    Cys (16) 
      .    Asn (16) 
Trp (3)   Leu (13)      
 1) Only residues that occur in more than 10 kinase domains are shown, with the 
exception of Trp at position 277. Aurora kinase residues are marked in bold and 
underlined.
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aAsp274
Val279
Ala213
Phe275
Leu139
Leu194
Ala273
Val147
b
c
Chain A       Chain B       Chain A
Leu139
Glu217Gly216 Asn261
Asp274
Val279
Phe275
benzoic
acid difluoro-
phenyl
Leu263
Gly-rich
loop
Leu139
Glu217Gly216 Asn261
Asp274
Val279
Phe275
benzoic
acid difluoro-
phenyl
Leu263
Gly-rich
loop Leu139
Thr217
Gly216 Asn261
Asp274
Val279
Phe275
difluoro-
phenyl
Leu263
Gly-rich
loop
AurAx3/MLN8054      AurAx3/MLN8054         AurAAA/8054-like AurAx3/MLN8054
Chain A
Chain A                Chain B                            Chain A
AurAx3/MLN8054   AurAx3/MLN8054             AurAAA/8054-like
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ba
c
Activation loop
A - Ala273 
D - Asp274 
F - Phe275 
G - Gly276 
W - Trp277 
S - Ser278 
V - Val279
pThr288
pThr287
pThr288
pThr287
Glu181
quinazoline-13
A D
F
W
His254
Lys162
?C
Arg255
Glu181
quinazoline-13
A D
F
W
His254
Lys162
?C
Arg255
Glu181
MLN8054 F
A
D
W
V
Arg255
Lys162 ?C
His254
S
Glu181
MLN8054 F
A
D
W
V
Arg255
Lys162 ?C
His254
S
Glu181
Lys162
ADP V
W
F
D
A
?C
His254
Arg255
S
Glu181
Lys162
ADP V
W
F
D
A
?C
His254
Arg255
S
F F
AurAx3/
MLN8054
(DFG-up)
AurA/ADP 
(DFG-in)
AurA/
quinazoline-13
(DFG-out)
cABL/
Glivec variant
(DFG-out) Leu210
Glu181
Leu208
Leu178
D
G
WA
?C
VMLN8054
F
Leu210
Glu181
Leu208
Leu178
D
G
WA
VMLN8054
F
?C
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Gly-rich
loop
Val147
Leu139
DFG-out
quinazoline-13
MLN8054
DFG-in
ADP
P
Mg2+
Phe275
Phe275
Phe275
Asp274
Asp274
Asp274
?-PO4 space
?-PO4 space
?-PO4 space
ADP
quinazoline-13
MLN8054
DFG-up
Mg2+
?-PO4
a     b
c     d
e
?-PO4
Activation loop
(MLN8054)
Asp274
(MLN8054)
Asp274
(ADP)
Gly-rich loop
Activation loop Asp274
(ADP)
Activation loop
(ADP)
Gly-rich loop 
(ADP)
Activation loop
(MLN8054)90o
(ADP)
difluorophenyl
(MLN8054)
?-PO4
(ADP)
difluorophenyl
(MLN8054)
Asp274
Gly140
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